Format

Send to

Choose Destination
Int J Pharm. 2016 Jul 25;509(1-2):59-70. doi: 10.1016/j.ijpharm.2016.05.035. Epub 2016 May 20.

Particulate systems based on pectin/chitosan association for the delivery of manuka honey components and platelet lysate in chronic skin ulcers.

Author information

1
Department of Drug Science, University of Pavia, Pavia, Italy.
2
Department of Drug Science, University of Pavia, Pavia, Italy. Electronic address: silvia.rossi@unipv.it.
3
Department of Public Health, Experimental and Forensic Medicine, Histology and Embryology Unit, University of Pavia, Pavia, Italy.
4
Immunohaematology and Transfusion Service and Cell Therapy Unit of Fondazione IRCCS, S. Matteo, Pavia, Italy.

Abstract

The aim of the present work was the development of a powder formulation for the delivery of manuka honey (MH) bioactive components and platelet lysate (PL) in chronic skin ulcers. In particular pectin (PEC)/chitosan (CS) particles were prepared by ionotropic gelation in the presence of calcium chloride and subsequently characterized for particle size, hydration properties and mechanical resistance. Different experimental conditions (calcium chloride and CS concentrations; rest time in the cationic solution) were considered in order to obtain particles characterized by optimal size, hydration properties and mechanical resistance. Two different fractions of MH were examined: one (Fr1), rich in methylglyoxal and the other (Fr2), rich in polyphenols. Particles were loaded with Fr1, fraction able to enhance in vitro proliferation of human fibroblasts, and with PL. The presence of CS in Fr1-loaded particles produced an improvement in cell proliferation. Moreover, PL loading into particles did not affect the biological activity of the hemoderivative. In vivo efficacy of PL- and Fr1-loaded particles was evaluated on a rat wound model. Both treatments markedly increased wound healing to the same extent.

KEYWORDS:

Chitosan; Manuka honey; Pectin; Platelet lysate; Polymeric particles; Wound healing

PMID:
27215534
DOI:
10.1016/j.ijpharm.2016.05.035
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center